This report provides a comprehensive analysis of the global Oligonucleotide Drug CDMO Services market, examining its trajectory from 2025 through 2032. It covers essential outsourcing solutions, including R&D, clinical material production, and commercial manufacturing for both SME and large pharmaceutical companies. By evaluating key segments such as API and preparation across major regions like the Americas, APAC, and Europe, the study highlights market drivers and competitive strategies of leading players including Bachem and WuXi TIDES.

Market Overview

The global Oligonucleotide Drug CDMO Services market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate over the forecast period.

Definition and Service Scope

Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production, and related services of oligonucleotide drugs.

Key services generally include:

• R&D services
• Production of clinical trial materials
• Commercial production
• Quality control and analysis
• Registration and compliance support

Value Proposition: Through these services, CDMOs help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.

Regional Market Analysis

The report provides detailed projections for the following regions, all of which are expected to see growth between 2025 and 2032:

• United States: Expected to increase from 2025 levels through 2032 at a sustained CAGR.
• China: Expected to increase from 2025 levels through 2032 at a sustained CAGR.
• Europe: Expected to increase from 2025 levels through 2032 at a sustained CAGR.

Market Segmentation

By Type

• API
• Preparation

By Application

• SME Pharmaceutical Company
• Large Pharmaceutical Company

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key Market Dynamics

The global market features significant competition, with the two largest companies occupying a substantial portion of the market share in 2025. This Insight Report highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Strategic Analysis

The report analyzes the strategies of leading global companies, focusing on:

• Oligonucleotide Drug CDMO Services portfolios and capabilities
• Market entry strategies
• Market positions
• Geographic footprints

Profiled Companies

The following companies have been selected based on primary expert input and analysis of company coverage, product portfolio, and market penetration:

• Bachem
• WuXi TIDES
• Ajinomoto Co
• Waters
• AGC Biologics
• Merck KGaA
• EUROAPI
• CordenPharma
• Cytiva
• TriLink BioTechnologies
• Medicilon
• General Biol
• BioSpring
• Bio-Synthesis Inc
• Aurisco
• Suzhou Olipharma Co.,Ltd
• Porton
• RIBOPharm

About the Research Report

LPI (LP Information)'s newest research report, the “Oligonucleotide Drug CDMO Services Industry Forecast,” reviews total world Oligonucleotide Drug CDMO Services sales in 2025. It provides a comprehensive analysis by region and market sector of projected sales for 2026 through 2032.

Report Features:

• Detailed Breakdown: Sales are broken down by region, market sector, and sub-sector, provided in US$ millions.
• Comprehensive Scope: Covers market shares, growth opportunities, and key regions/countries.
• Methodology: Utilizes a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs to offer a nuanced view of the current state and future trajectory of the global industry.
• Opportunity Identification: Evaluates key market trends, drivers, and affecting factors to highlight emerging pockets of opportunity.

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Oligonucleotide Drug CDMO Services Market Size (2021-2032)

    • 2.1.2 Oligonucleotide Drug CDMO Services Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Oligonucleotide Drug CDMO Services by Country/Region (2021, 2025 & 2032)

  • 2.2 Oligonucleotide Drug CDMO Services Segment by Type

    • 2.2.1 API

    • 2.2.2 Preparation

    • 2.2.3 Oligonucleotide Drug CDMO Services Market Size by Type

      • 2.2.3.1 Oligonucleotide Drug CDMO Services Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.3.2 Global Oligonucleotide Drug CDMO Services Market Size Market Share by Type (2021-2026)

  • 2.3 Oligonucleotide Drug CDMO Services Segment by Application

    • 2.3.1 SME Pharmaceutical Company

    • 2.3.2 Large Pharmaceutical Company

    • 2.3.3 Oligonucleotide Drug CDMO Services Market Size by Application

      • 2.3.3.1 Oligonucleotide Drug CDMO Services Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.3.2 Global Oligonucleotide Drug CDMO Services Market Size Market Share by Application (2021-2026)

• 3 Oligonucleotide Drug CDMO Services Market Size by Player

  • 3.1 Oligonucleotide Drug CDMO Services Market Size Market Share by Player

    • 3.1.1 Global Oligonucleotide Drug CDMO Services Revenue by Player (2021-2026)

    • 3.1.2 Global Oligonucleotide Drug CDMO Services Revenue Market Share by Player (2021-2026)

  • 3.2 Global Oligonucleotide Drug CDMO Services Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Oligonucleotide Drug CDMO Services by Region

  • 4.1 Oligonucleotide Drug CDMO Services Market Size by Region (2021-2026)

  • 4.2 Global Oligonucleotide Drug CDMO Services Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Oligonucleotide Drug CDMO Services Market Size Growth (2021-2026)

  • 4.4 APAC Oligonucleotide Drug CDMO Services Market Size Growth (2021-2026)

  • 4.5 Europe Oligonucleotide Drug CDMO Services Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)

  • 5.2 Americas Oligonucleotide Drug CDMO Services Market Size by Type (2021-2026)

  • 5.3 Americas Oligonucleotide Drug CDMO Services Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Oligonucleotide Drug CDMO Services Market Size by Region (2021-2026)

  • 6.2 APAC Oligonucleotide Drug CDMO Services Market Size by Type (2021-2026)

  • 6.3 APAC Oligonucleotide Drug CDMO Services Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)

  • 7.2 Europe Oligonucleotide Drug CDMO Services Market Size by Type (2021-2026)

  • 7.3 Europe Oligonucleotide Drug CDMO Services Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Oligonucleotide Drug CDMO Services by Region (2021-2026)

  • 8.2 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Oligonucleotide Drug CDMO Services Market Forecast

  • 10.1 Global Oligonucleotide Drug CDMO Services Forecast by Region (2027-2032)

    • 10.1.1 Global Oligonucleotide Drug CDMO Services Forecast by Region (2027-2032)

    • 10.1.2 Americas Oligonucleotide Drug CDMO Services Forecast

    • 10.1.3 APAC Oligonucleotide Drug CDMO Services Forecast

    • 10.1.4 Europe Oligonucleotide Drug CDMO Services Forecast

    • 10.1.5 Middle East & Africa Oligonucleotide Drug CDMO Services Forecast

  • 10.2 Americas Oligonucleotide Drug CDMO Services Forecast by Country (2027-2032)

    • 10.2.1 United States Market Oligonucleotide Drug CDMO Services Forecast

    • 10.2.2 Canada Market Oligonucleotide Drug CDMO Services Forecast

    • 10.2.3 Mexico Market Oligonucleotide Drug CDMO Services Forecast

    • 10.2.4 Brazil Market Oligonucleotide Drug CDMO Services Forecast

  • 10.3 APAC Oligonucleotide Drug CDMO Services Forecast by Region (2027-2032)

    • 10.3.1 China Oligonucleotide Drug CDMO Services Market Forecast

    • 10.3.2 Japan Market Oligonucleotide Drug CDMO Services Forecast

    • 10.3.3 Korea Market Oligonucleotide Drug CDMO Services Forecast

    • 10.3.4 Southeast Asia Market Oligonucleotide Drug CDMO Services Forecast

    • 10.3.5 India Market Oligonucleotide Drug CDMO Services Forecast

    • 10.3.6 Australia Market Oligonucleotide Drug CDMO Services Forecast

  • 10.4 Europe Oligonucleotide Drug CDMO Services Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Oligonucleotide Drug CDMO Services Forecast

    • 10.4.2 France Market Oligonucleotide Drug CDMO Services Forecast

    • 10.4.3 UK Market Oligonucleotide Drug CDMO Services Forecast

    • 10.4.4 Italy Market Oligonucleotide Drug CDMO Services Forecast

    • 10.4.5 Russia Market Oligonucleotide Drug CDMO Services Forecast

  • 10.5 Middle East & Africa Oligonucleotide Drug CDMO Services Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Oligonucleotide Drug CDMO Services Forecast

    • 10.5.2 South Africa Market Oligonucleotide Drug CDMO Services Forecast

    • 10.5.3 Israel Market Oligonucleotide Drug CDMO Services Forecast

    • 10.5.4 Turkey Market Oligonucleotide Drug CDMO Services Forecast

  • 10.6 Global Oligonucleotide Drug CDMO Services Forecast by Type (2027-2032)

  • 10.7 Global Oligonucleotide Drug CDMO Services Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Oligonucleotide Drug CDMO Services Forecast

• 11 Key Players Analysis

  • 11.1 Bachem

    • 11.1.1 Bachem Company Information

    • 11.1.2 Bachem Oligonucleotide Drug CDMO Services Product Offered

    • 11.1.3 Bachem Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Bachem Main Business Overview

    • 11.1.5 Bachem Latest Developments

  • 11.2 WuXi TIDES

    • 11.2.1 WuXi TIDES Company Information

    • 11.2.2 WuXi TIDES Oligonucleotide Drug CDMO Services Product Offered

    • 11.2.3 WuXi TIDES Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 WuXi TIDES Main Business Overview

    • 11.2.5 WuXi TIDES Latest Developments

  • 11.3 Ajinomoto Co

    • 11.3.1 Ajinomoto Co Company Information

    • 11.3.2 Ajinomoto Co Oligonucleotide Drug CDMO Services Product Offered

    • 11.3.3 Ajinomoto Co Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Ajinomoto Co Main Business Overview

    • 11.3.5 Ajinomoto Co Latest Developments

  • 11.4 Waters

    • 11.4.1 Waters Company Information

    • 11.4.2 Waters Oligonucleotide Drug CDMO Services Product Offered

    • 11.4.3 Waters Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Waters Main Business Overview

    • 11.4.5 Waters Latest Developments

  • 11.5 AGC Biologics

    • 11.5.1 AGC Biologics Company Information

    • 11.5.2 AGC Biologics Oligonucleotide Drug CDMO Services Product Offered

    • 11.5.3 AGC Biologics Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 AGC Biologics Main Business Overview

    • 11.5.5 AGC Biologics Latest Developments

  • 11.6 Merck KGaA

    • 11.6.1 Merck KGaA Company Information

    • 11.6.2 Merck KGaA Oligonucleotide Drug CDMO Services Product Offered

    • 11.6.3 Merck KGaA Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Merck KGaA Main Business Overview

    • 11.6.5 Merck KGaA Latest Developments

  • 11.7 EUROAPI

    • 11.7.1 EUROAPI Company Information

    • 11.7.2 EUROAPI Oligonucleotide Drug CDMO Services Product Offered

    • 11.7.3 EUROAPI Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 EUROAPI Main Business Overview

    • 11.7.5 EUROAPI Latest Developments

  • 11.8 CordenPharma

    • 11.8.1 CordenPharma Company Information

    • 11.8.2 CordenPharma Oligonucleotide Drug CDMO Services Product Offered

    • 11.8.3 CordenPharma Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 CordenPharma Main Business Overview

    • 11.8.5 CordenPharma Latest Developments

  • 11.9 Cytiva

    • 11.9.1 Cytiva Company Information

    • 11.9.2 Cytiva Oligonucleotide Drug CDMO Services Product Offered

    • 11.9.3 Cytiva Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Cytiva Main Business Overview

    • 11.9.5 Cytiva Latest Developments

  • 11.10 TriLink BioTechnologies

    • 11.10.1 TriLink BioTechnologies Company Information

    • 11.10.2 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Product Offered

    • 11.10.3 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 TriLink BioTechnologies Main Business Overview

    • 11.10.5 TriLink BioTechnologies Latest Developments

  • 11.11 Medicilon

    • 11.11.1 Medicilon Company Information

    • 11.11.2 Medicilon Oligonucleotide Drug CDMO Services Product Offered

    • 11.11.3 Medicilon Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Medicilon Main Business Overview

    • 11.11.5 Medicilon Latest Developments

  • 11.12 General Biol

    • 11.12.1 General Biol Company Information

    • 11.12.2 General Biol Oligonucleotide Drug CDMO Services Product Offered

    • 11.12.3 General Biol Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 General Biol Main Business Overview

    • 11.12.5 General Biol Latest Developments

  • 11.13 BioSpring

    • 11.13.1 BioSpring Company Information

    • 11.13.2 BioSpring Oligonucleotide Drug CDMO Services Product Offered

    • 11.13.3 BioSpring Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 BioSpring Main Business Overview

    • 11.13.5 BioSpring Latest Developments

  • 11.14 Bio-Synthesis Inc

    • 11.14.1 Bio-Synthesis Inc Company Information

    • 11.14.2 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Product Offered

    • 11.14.3 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 Bio-Synthesis Inc Main Business Overview

    • 11.14.5 Bio-Synthesis Inc Latest Developments

  • 11.15 Aurisco

    • 11.15.1 Aurisco Company Information

    • 11.15.2 Aurisco Oligonucleotide Drug CDMO Services Product Offered

    • 11.15.3 Aurisco Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.15.4 Aurisco Main Business Overview

    • 11.15.5 Aurisco Latest Developments

  • 11.16 Suzhou Olipharma Co.,Ltd

    • 11.16.1 Suzhou Olipharma Co.,Ltd Company Information

    • 11.16.2 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Product Offered

    • 11.16.3 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.16.4 Suzhou Olipharma Co.,Ltd Main Business Overview

    • 11.16.5 Suzhou Olipharma Co.,Ltd Latest Developments

  • 11.17 Porton

    • 11.17.1 Porton Company Information

    • 11.17.2 Porton Oligonucleotide Drug CDMO Services Product Offered

    • 11.17.3 Porton Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.17.4 Porton Main Business Overview

    • 11.17.5 Porton Latest Developments

  • 11.18 RIBOPharm

    • 11.18.1 RIBOPharm Company Information

    • 11.18.2 RIBOPharm Oligonucleotide Drug CDMO Services Product Offered

    • 11.18.3 RIBOPharm Oligonucleotide Drug CDMO Services Revenue, Gross Margin and Market Share (2021-2026)

    • 11.18.4 RIBOPharm Main Business Overview

    • 11.18.5 RIBOPharm Latest Developments

• 12 Research Findings and Conclusion